Inovio Pharmaceuticals (INO) Accounts Payables (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Accounts Payables of $11.1 million for Q4 2025, up 2808.85% sequentially from $380000.0 in Q3 2025, and up 718.08% YoY from $1.4 million in Q4 2024.
Inovio Pharmaceuticals (INO) Accounts Payables (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Accounts Payables for 16 years, with the latest figure at $11.1 million in Q4 2025.
- Quarterly Accounts Payables rose 718.08% year-over-year to $11.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.1 million (up 718.08% YoY) and the FY2025 annual result came in at $11.1 million, up 718.08% from the prior year.
- Accounts Payables advanced to $11.1 million in Q4 2025 per INO's latest filing, from $380000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $105.0 million in Q2 2022 and troughed at $369370.0 in Q2 2025.
- A 5-year average of $20.8 million and a median of $6.5 million in 2024 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 1526.28% in 2023, down 99.04% in 2023.
- Over 5 years, Accounts Payables stood at $47.6 million in 2021, then slumped by 97.44% to $1.2 million in 2022, then surged by 1526.28% to $19.8 million in 2023, then slumped by 93.19% to $1.4 million in 2024, then jumped by 718.08% to $11.1 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $11.1 million, $380000.0, and $369370.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | 11.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.65 Mn |
| Mar 31, 2026 | 9.27 Mn |
| Dec 31, 2025 | 11.05 Mn |
| Sep 30, 2025 | 380,000.00 |
| Jun 30, 2025 | 369,370.00 |
| Mar 31, 2025 | 470,000.00 |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 19.85 Mn |
| Sep 30, 2023 | 711,720.00 |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 24.75 Mn |
| Dec 31, 2022 | 1.22 Mn |
| Sep 30, 2022 | 74.15 Mn |
| Jun 30, 2022 | 105.02 Mn |
| Mar 31, 2022 | 38.12 Mn |
| Dec 31, 2021 | 47.64 Mn |
| Sep 30, 2021 | 28.65 Mn |